Brokerages Set OrthoPediatrics Corp. (NASDAQ:KIDS) Target Price at $35.83

OrthoPediatrics Corp. (NASDAQ:KIDS) has received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $35.83.

Several research analysts recently weighed in on KIDS shares. Truist Financial cut their target price on shares of OrthoPediatrics from $26.00 to $24.00 and set a “hold” rating for the company in a research note on Friday, April 11th. Needham & Company LLC reiterated a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a report on Thursday, May 8th. Stifel Nicolaus decreased their target price on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Piper Sandler decreased their price target on OrthoPediatrics from $40.00 to $30.00 and set an “overweight” rating for the company in a report on Thursday, May 8th. Finally, Lake Street Capital initiated coverage on OrthoPediatrics in a report on Monday, April 7th. They issued a “buy” rating and a $37.00 price target for the company.

Insider Buying and Selling at OrthoPediatrics

In related news, CEO David R. Bailey sold 6,620 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the sale, the chief executive officer now directly owns 319,155 shares of the company’s stock, valued at approximately $7,934,193.30. This represents a 2.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Gregory A. Odle sold 5,359 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $133,224.74. Following the sale, the insider now directly owns 148,788 shares in the company, valued at approximately $3,698,869.68. This represents a 3.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,732 shares of company stock valued at $589,978 in the last three months. Corporate insiders own 32.70% of the company’s stock.

Institutional Investors Weigh In On OrthoPediatrics

Several large investors have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its stake in shares of OrthoPediatrics by 3.0% in the fourth quarter. Invesco Ltd. now owns 16,363 shares of the company’s stock worth $379,000 after purchasing an additional 469 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of OrthoPediatrics by 0.3% during the fourth quarter. Northern Trust Corp now owns 193,798 shares of the company’s stock valued at $4,492,000 after purchasing an additional 644 shares during the last quarter. Rhumbline Advisers boosted its position in OrthoPediatrics by 4.1% during the 4th quarter. Rhumbline Advisers now owns 26,411 shares of the company’s stock worth $612,000 after acquiring an additional 1,042 shares during the period. R Squared Ltd purchased a new stake in OrthoPediatrics in the 4th quarter worth approximately $48,000. Finally, Bank of New York Mellon Corp lifted its position in OrthoPediatrics by 3.8% in the 4th quarter. Bank of New York Mellon Corp now owns 57,710 shares of the company’s stock worth $1,338,000 after buying an additional 2,099 shares in the last quarter. 69.05% of the stock is owned by institutional investors and hedge funds.

OrthoPediatrics Price Performance

Shares of NASDAQ KIDS opened at $22.85 on Thursday. The firm has a market capitalization of $554.96 million, a P/E ratio of -18.58 and a beta of 1.09. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. OrthoPediatrics has a one year low of $20.25 and a one year high of $35.99. The company’s fifty day moving average is $22.94 and its two-hundred day moving average is $24.03.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.13). OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The firm had revenue of $52.41 million for the quarter, compared to analyst estimates of $51.68 million. Analysts forecast that OrthoPediatrics will post -0.93 EPS for the current fiscal year.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.